Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 10/20 | 0.48 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 3/20 | 0.42 |
| ▸ | CCR3 | P51677 | 3/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.42 |
| ▸ | SPR | P35270 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | AXL | P30530 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2916325 | 0.86 | KDM4E (0.54) | HRH1CCR3KCNH2MAPT | |
| SCHEMBL2922964 | 0.80 | KDM4E (0.54) | HRH1CCR3SPRKCNH2MAPT | |
| SCHEMBL2915155 | 0.79 | NR4A2 (0.51) | NR4A2CREBBPMAP2K1AXL | |
| SCHEMBL2923905 | 0.77 | PTGS2 (0.39) | PTGS1PTGS2MAPT | |
| SCHEMBL926243 | 0.76 | NR4A2 (0.68) | NR4A2CREBBPMAP2K1AXL | |
| SCHEMBL2918231 | 0.73 | PARP1 (0.54) | NR4A2CREBBPMAP2K1AXL | |
| SCHEMBL21709859 | 0.72 | HSD17B10 (0.45) | PTGS1PTGS2 | |
| SCHEMBL30007360 | 0.71 | AXL (0.72) | NR4A2MAP2K1AXL | |
| SCHEMBL6182266 | 0.70 | KDM4E (0.50) | PTGS2MAPT | |
| SCHEMBL2642601 | 0.70 | LMNA (0.47) | PTGS2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1478624-B1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-08 | — | — | EP | disclosed |
| EP-1478624-B1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-08 | — | — | EP | disclosed |
| US-7709500-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-7709500-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-7709500-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| CN-100564358-C | The method of a kind of preparation 4-(3, the 4-dichlorophenoxy) piperidines | ASTRAZENECA AB (SE) | 2009-12-02 | — | — | CN | disclosed |
| CN-100352807-C | substituted piperidine compounds | ASTRAZENECA AB (SE) | 2007-12-05 | — | — | CN | disclosed |
| CN-1907968-A | Method for making 4-(3,4-dichlorophenoxy)piperidine | ASTRAZENECA AB (SE) | 2007-02-07 | — | — | CN | disclosed |
| CN-1633414-A | Compound (I) | ASTRAZENECA AB (SE) | 2005-06-29 | — | — | CN | disclosed |
| US-20050107428-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | US | disclosed |
| EP-1478624-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003068743-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107428-A1 | Chemical compounds | CCR10, CCR3, CXCR5 | NR4A2 67/4885CREBBP 1421/4885HRH1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.